Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.00% $32.48
America/New_York / 21 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 3 728.22 mill |
EPS: | -0.990 |
P/E: | -32.81 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 114.79 mill |
Avg Daily Volume: | 4.16 mill |
RATING 2024-03-21 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -32.81 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-5.58x |
Company: PE -32.81 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$4.85 (-85.07%) $-27.63 |
Date: 2024-03-26 |
Expected Trading Range (DAY) |
---|
$ 31.92 - 33.04 ( +/- 1.74%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-22 | Loewy Caroline M | Sell | 30 000 | Employee Stock Option (right to buy) |
2024-03-22 | Loewy Caroline M | Sell | 15 000 | Employee Stock Option (right to buy) |
2024-03-22 | Loewy Caroline M | Sell | 7 500 | Employee Stock Option (right to buy) |
2024-03-22 | Loewy Caroline M | Sell | 16 000 | Employee Stock Option (right to buy) |
2024-03-22 | Loewy Caroline M | Sell | 27 705 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
-97.48 |
Last 100 transactions |
Buy: 127 470 | Sell: 9 848 383 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $32.48 (0.00% ) |
Volume | 0 mill |
Avg. Vol. | 4.16 mill |
% of Avg. Vol | 0 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $24.86 | N/A | Active |
---|
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.